SAN DIEGO, July 31, 2012 /PRNewswire/ -- Gen-Probe
Incorporated (NASDAQ: GPRO) today announced that its stockholders,
at a special meeting held today, voted to adopt the agreement and
plan of merger among Gen-Probe, Hologic, Inc. (NASDAQ: HOLX) and
Gold Acquisition Corp., a direct wholly owned subsidiary of
Hologic. Adoption of the agreement and plan of merger
required the affirmative vote of the holders of a majority of the
outstanding shares of Gen-Probe's common stock entitled to
vote.
(Logo: http://photos.prnewswire.com/prnh/20120312/LA68580LOGO)
The merger is expected to close on Wednesday, August 1, 2012. As a result of
the merger, Gen-Probe will become a wholly owned subsidiary of
Hologic, and Gen-Probe's stockholders (except for Gen-Probe
stockholders who have properly exercised rights of appraisal) will
be entitled to receive $82.75 in
cash, without interest, for each share of Gen-Probe common stock
that they own.
About Gen-Probe
Gen-Probe is a global leader in the development,
manufacture and marketing of rapid, accurate and cost-effective
molecular diagnostic products and services that are used primarily
to diagnose human diseases, screen donated human blood, and ensure
transplant compatibility. Gen-Probe is headquartered in
San Diego and employs
approximately 1,400 people. For more information, go to
http://www.gen-probe.com.
Caution Regarding Forward-Looking Statements
Any statements in this news release about our expectations,
beliefs, plans, objectives, assumptions or future events or
performance are forward-looking statements. These statements
are often made through the use of words or phrases such as believe,
will, expect, anticipate, estimate, intend, plan and would.
For example, statements concerning possible or expected results of
operations, regulatory approvals, future sales, growth
opportunities, and plans of management are all forward-looking
statements. Forward-looking statements are not guarantees of
performance. They involve known and unknown risks,
uncertainties and assumptions that may cause actual results to
differ materially from those expressed or implied. Some of
these risks include: (i) the ability of the parties to consummate
the proposed acquisition in a timely manner or at all; (ii)
satisfaction of the other conditions precedent to consummation of
the proposed acquisition; (iii) uncertainties relating to
litigation, including pending and future Gen-Probe stockholder
lawsuits related to the proposed acquisition; and (iv) successful
and timely completion by Hologic of its anticipated
financing arrangements for the acquisition. This list
includes some, but not all, of the factors that could affect our
ability to achieve results described in any forward-looking
statements. For additional information about risks and
uncertainties we face and a discussion of our financial statements
and footnotes, see documents we file with the SEC. We assume
no obligation and expressly disclaim any duty to update
forward-looking statements to reflect events or circumstances after
the date of this news release or to reflect the occurrence of
subsequent events.
Contact:
Al Kildani
Sr. director, investor relations and
corporate communications
818-410-8653
SOURCE Gen-Probe Incorporated